mFluiDx is pioneering a point-of-care molecular diagnostic technology known as the "SIMPLE CHIP," which aims to provide rapid and cost-effective testing for multiple pathogens, including bacteria and viruses. This innovative platform utilizes microfluidics technology to create low-cost consumable cartridges and reader instruments, enabling simultaneous detection of various infectious agents from a single patient sample. The SIMPLE CHIP is designed for quick turnaround times, with results available in approximately 7 to 15 minutes, and boasts high sensitivity and specificity through the use of isothermal amplification methods that deliver performance comparable to traditional PCR tests. 

The automation of the testing process is a key feature of mFluiDx's technology, allowing for a fully integrated sample-to-answer workflow that includes sample preparation. This capability is particularly beneficial for decentralized testing environments such as small clinics and pharmacies, facilitating immediate on-site screening. The development of this technology has garnered support from notable organizations, including the Gates Foundation, and has been recognized in various startup accelerators and funding programs, highlighting its potential impact on public health and infectious disease management.

United States

mFluiDx is a UC Berkeley spinout startup that develops innovative technology to enable rapid, low-cost molecular DNA/RNA diagnostics at point-of-care.

mFluiDx

Company Details